An event titled "AmaZyng! A New Treatment Option for R/R DLBCL," organized by Sobi, was recently held in Bologna. The meeting was attended by leading figures in the medical field, particularly hematologists and hematologists-oncohematologists, both nationally and internationally. The main topic of discussion was the introduction of a new treatment for diffuse large B-cell lymphoma.
A New Treatment in Clinical Practice
The treatment in question, known as loncastuximab tesirine, has been accepted into clinical practice in Italy since March of this year. It represents a new therapeutic option for adult patients with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after two or more lines of systemic therapy.
It might interest you
Ambulance hits 12-year-old on his way to school; he's in serious condition.
Fake postal police officers in action: €5.500 scam foiled
A Europe-wide hunt is underway for Taulant Toma, the prisoner who went on a diet to pass behind bars.
Italy's corruption crisis is sinking: Campania has a record number of people under investigation.
The event featured experts discussing the efficacy and potential of loncastuximab tesirine, providing updates and insights into how this therapy may impact the treatment of these forms of lymphoma.
Comments (1)
The event in Bologna on diffuse large B-cell lymphoma was a great opportunity to better understand the news. The discussion on loncastuximab tesirine was very interesting, but I noticed that there are still doubts among doctors about its efficacy.